Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Haugen MH, Engebraaten O(2025) High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy Breast Cancer Res, 27(1), 143 DOI 10.1186/s13058-025-02092-9, PubMed 40790765
Demeestere I, Niman SM, Partridge AH, Diego DS, Kammler R, Ruggeri M, Colleoni M, Shimizu C, Saura C, Gelmon KA, Saetersdal AB, Kroep JR, Mailliez A, Amant F, Ruız-Borrego M, Lee JE, Kataoka A, Walshe JM, Takei J, Borstnar S, Borges VF, Saunders C, Susnjar S, Bjelic-Radisic V, Cardoso Fet al.(2025) Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial Breast, 83, 104547(in press) DOI 10.1016/j.breast.2025.104547, PubMed 40743662
Gabrielsen E, Wilsgaard T, Frydenberg H, Lofterød T, Dalen SM, Mortensen E, Solbu MD, Nalwoga H, Akslen LA, Blix ES, Haugnes HS(2025) Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study Breast Cancer Res Treat(in press) DOI 10.1007/s10549-025-07786-4, PubMed 40694191
